1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Approved pharmacologic agents for treatment of osteoporosis
Drug (Brand names) Dose^† Proven Fracture Reduction^* Indication
Alendronate (Fosamax) 10 mg daily, 70 mg weekly Vertebral, hip, nonvertebral Postmenopausal women, men; glucocorticoid-induced osteoporosis
Risedronate (Actonel) 5 mg daily, 35 mg weekly, 75 mg 2 days/month Vertebral, hip, nonvertebral Postmenopausal women, men; glucocorticoid-induced osteoporosis
Ibandronate (Boniva) 2.5 mg daily, 150 mg monthly, 3 mg IV every 3 months Vertebral, nonvertebral Postmenopausal women
Zoledronic acid (Reclast, Zometa) 5 mg IV yearly Vertebral, hip, nonvertebral Postmenopausal women
Raloxifene (Evista) 60 mg daily Vertebral Postmenopausal women
Salmon calcitonin (Miacalcin, Fortical) 200 U intranasally daily Vertebral Postmenopausal women
Teriparatide (Forteo) 20 mcg subcutaneously daily for ≤2 years Vertebral, nonvertebral Postmenopausal women
Note:—IV indicates intravenous.
* In postmenopausal women with osteoporosis.
† Oral unless otherwise noted.